Topical vaginal sustained delivery of siRNA presents a significant challenge due to the short residence time of formulations. Therefore, a drug delivery system capable to adhere to the vaginal mucosa is desirable, as it could allow a prolonged delivery and increase the effectiveness of the therapy. The aim of this project is to develop a polymeric solid mucoadhesive system, loaded with lipoplexes, able to be progressively rehydrated by the vaginal fluids to form a hydrogel and to deliver siRNA to vaginal tissues. This study demonstrates the feasibility of entrapping pegylated lipoplexes into a solid matrix system for a prolonged delivery of siRNA into the vagina.
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Introduction 1
In the context of genital diseases, the vaginal route of administration has gained great attention 2 for drug delivery and has been extensively studied for effective delivery of different drug 3 molecules [1] [2] [3] . Advantages over other routes of drug administration include low drug doses, 4 reduced risk of systemic immune activation, site-specific delivery, and most importantly, 5 circumvention of first-pass hepatic clearance [4] . The ease of administration and low toxicity 6 profile make the vaginal route an excellent site for the delivery of many drugs and particularly 7 for siRNA delivery for the treatment and prevention of vaginal and/or cervical diseases [5] [6] [7] . 8
However, naked siRNAs have difficulties in achieving efficient mucosal uptake if administered 9 directly into the vagina due to degradation, poor cellular uptake, low mucus diffusion and high 10 clearance. In order to overcome these obstacles, siRNA need to be encapsulated in a vector, 11 such as liposomes. 12
Liposomes have been largely investigated as vaginal drug delivery system [8] [9] [10] [11] . However, 13
vaginal conditions are subject to changes because of numerous physiological and non-14 physiological factors that can lead to variations in the bioavailability of drugs. Moreover, a 15 vaginal administration of lipoplexes (liposomes encapsulating siRNA) encounters important 16 barriers such as the penetration through the mucus to reach the epithelial tissue and a short 17 residence time. One strategy to improve the particle diffusion through the mucus and to create 18 "mucopenetrating" lipoplexes is to densely coat their surface with polyethylene glycol (PEG) 19 [1, 12, 13] . PEG is a neutral hydrophilic polymer that has been described to minimize adhesive 20 interactions between nanoparticles and mucus components, allowing them to penetrate rapidly 21 through viscoelastic human mucus secretions [14, 15] . The size of the lipoplexes is also 22 another important parameter to consider for the diffusion. It has been shown that particles with 23 a diameter around 200 -300 nm can diffuse more rapidly through undiluted human vaginal 24 mucus, than smaller ones (100 nm) and bigger ones (> 500 nm) [16, 17] . 25
Unfortunately, even if lipoplexes are mucopenetrating, they have a short residence time, which 26 conducts them to be quickly eliminated. In order to improve the vaginal retention, lipoplexes 27 should be incorporated in an appropriate depot system with a desirable viscosity and with 28 mucoadhesive properties. For this purpose, a polymeric hydrogel can be a good solution [18] . 29
Among the different mucoadhesive polymers used for vaginal administration and based on 30 previous results [19] [20] [21] , cellulosic derivatives and particularly hydroxyethyl cellulose (HEC) 31 are attractive candidates. It has also been described that lipid vesicles are compatible with 32 HEC hydrogels [22] . 33
Finally, in order to avoid drug degradation and to obtain a solid and easy to handle system, the 34 hydrogels containing pegylated lipoplexes should be freeze-dried. The obtained system, called 35 sponge, has been previously described and characterized [19] . 36
Taken together, increasing the residence time with the vaginal mucosa by introducing 37 pegylated lipoplexes inside a mucoadhesive solid system can be crucial for efficient vaginal 38 siRNA delivery. Combining mucoadhesion and prolonged drug delivery possesses the 39 advantages to improve patient's compliance and to reduce the frequency of application. 40
Here, we develop a novel solid matrix system able to adhere to the vaginal mucosa, to be in 41 situ rehydrated by the vaginal fluids to form a hydrogel and to deliver in a sustained manner 42 mucopenetrating pegylated lipoplexes and consequently siRNA to vaginal tissues under 43 pathological conditions. 44
c. Stability 101
Freeze-dried lipoplexes were stored in closed glass vials at 4°C for 25 days. The integrity of 102 complexed siRNA was assessed by agarose gel electrophoresis. Triton X-100 (0.5% w/v) was 103 used to break vesicles and release the complexed siRNA [23] . Gel retardation assay was 104 performed in the same conditions as described in section 2.2.3.b. 105
The mean diameter, the PdI and the zeta potential of the freeze-dried lipoplexes were also 106 measured, as described in section 2.2.3.a. 107 108
Sponges formulations 109

Preparation of placebo sponges 110
Hydrogels (6 g) were prepared by gradual dispersion in water of HEC polymer (0.83% or 111 1.67%) and PEG400 (0.41%), at room temperature and under magnetic stirring. Once 112 homogeneous aqueous dispersions were obtained, the hydrogels were then freeze-dried to 113 form sponges [19] . 114 115
Preparation of sponges loaded with lipoplexes 116
HEC (0.83% or 1.67%), PEG400 (0.41%) and trehalose (1%) were gradually dispersed in 117 lipoplexes (300 nM, 6 mL) suspension at room temperature and under magnetic stirring. The 118 obtained hydrogels containing lipoplexes were then freeze-dried as described above. 119 120
Preparation of artificial vaginal mucus 121
Simulated vaginal mucus (SVF) was prepared with NaCl (0.351 g), KOH (0.140 g), Ca(OH) 2 122 (0.022 g), bovine serum albumin (0.002 g), lactic acid (0.200 g), acetic acid (0.100 g), glycerol 123 (0.016 g), urea (0.040 g), glucose (0.500 g) and dried porcine gastric mucin (type 3) (1.5% w/v) 124 mixed to 90 mL of milliQ water [24, 25] . SVF was stirred until complete dispersion of the 125 components. The pH was adjusted to 6 using HCl (0.1 M) and the final volume was adjusted 126 to 100 mL with milliQ water. 127
Characterization 129
a. Mucoadhesion 130
The mucoadhesive strength (N) was determined using a Texture Analyzer (TA) (Lloyd 131
Instruments, Ametek Company) in compression mode and with hydrated mucin disc, as 132 described previously [19, 22] . Briefly, the sponges were attached with both side adhesive tape 133 on the table of the TA. The mucin disc fixed to the probe (13 mm diameter) was brought into 134 contact with the sponge with a preload of 0.1 N and was maintained for 60s to ensure intimate 135 contact. The probe was then elevated and the mucoadhesive strength was determined from 136 the detachment force between the disc and the sponge. The mucoadhesion of different 137 commercialized pharmaceutical products for vaginal administration (Gynodaktarin ® , Lubrilan ® , 138
Mithra Intim gel ® , Gynoxin ® , Lubexxx ® , Canestene ® , Crinone ® , Preventex ® ) was also measured 139 in the same condition in order to compare them to prepared sponges. 140
b. Hardness and deformability 141
The hardness (N) and the deformability (%) of the sponges were determined with a TA in 142 compression and cyclic mode. The sponges were attached with both side adhesive tape on 143 the table of the TA. A cylindrical probe (25 mm diameter) was compressed four times into each 144 sample with a preload of 0.5 N, at a defined rate (1 mm/s) and to a defined depth (0.2 mm). 145
The hardness is the force measured after the first compression. The deformability is the ratio 146 of the force obtained after the first compression and the force measured after each cycle. 147
c. Scanning Electron Microscopy and Energy Dispersive X-Ray Analysis (SEM-EDX) 148
Scanning electron microscopy (SEM) was performed on sponges loaded with lipoplexes using 149 a Field Emission Environmental microscope (Philips, model XL 30) after metallization with 150 platinum (30 nm). Elemental detection was also performed with this microscope without 151 preparation of the samples. The morphology of the lipoplexes was analysed. Lipoplexes were 152 identified by the phosphorus atom (P) of siRNA molecules. 153 154
Diffusion and colloidal stability of lipoplexes 155
Lipoplexes were prepared with fluo-siRNA (300 nM) and the sponges were loaded with 156 fluorescent lipoplexes, as described in sections 2.2.1. and 2.3.2. Sponges were previously 157 rehydrated with 2 mL of SVF at 37°C in order to mimic in situ vaginal conditions before 158 measuring the diffusion of lipoplexes. 159
Fluorescence Single Particle Tracking (fSPT) 160
For the analysis of lipoplexes inside mucus, 10 µL of lipoplexes were added to 40 µL of SVF 161 in a 8-well plate and for the analysis of lipoplexes loaded into rehydrated sponges, 50 µL were 162 sampled. Moreover, 10 µL of lipoplexes were added in 40 µL of RNAse free water, as a control 163 condition. Each sample was allowed to equilibrate for 15 min at 37°C before being placed on 164 the swept-field microscope (Nikon, Brussels, Belgium) equipped with a 60x oil immersion lens 165 (Nikon) and with a stage top incubator kept at 37°C. Movies were recorded with NIS Elements 166 software (Nikon) driving the Andor ixon ultra 897 camera (Belfast, UK). Analysis of the videos 167 was performed using an house-developed particle tracking software [26] . 168 169
Fluorescence Correlation Spectroscopy (FCS) 170
The samples were prepared in the same conditions as above (2.4.1.). They were placed in a 171 glass-bottom 96-well plate (Greiner bio-one, Frickenhausen, Germany) and the fluorescent 172 signal was measured respectively after 0 h, 2 h and 4 h of incubation at 37°C. FCS 173 measurements were performed on a C1si laser scanning confocal microscope (Nikon), 174 equipped with a time correlated single photon counting data acquisition module (Picoquant, 175
Berlin, Germany). The laser beam was held stationary and was focused through an oil 176 immersion objective lens (Plan Apo 60x, NA 1.2, collar rim correction, Nikon). The 647 nm 177 laser beam of krypton-argon laser (Bio-Rad, Cheshire, UK) was used and the red fluorescence 178 intensity fluctuations were recorded using Sympho-time (Picoquant, Berlin, Germany) for at 179 least 60 s. 180 181
Release study 182
The release rate of fluorescent lipoplexes from the sponges was monitored over time and 183 determined by fSPT technique. The sponges loaded with fluorescent lipoplexes were placed 184 on ThinCert ® with 0.4 µm pores diameter (PET membrane, Greiner bio-one) in a 6-well TC 185 plate (Cellstar, Greiner bio-one) and were rehydrated with 2 mL of SVF (figure 1). The acceptor 186 compartment was filled with SVF (2.5 mL) and all the system was incubated at 37°C. Every 187 hour during 6 h, 100 µL were collected and fSPT movies were recorded, as described in section 
Statistical analysis 197
All values are expressed as the mean ± SEM. Statistical analyses were performed using 198 GraphPad Prism ® software. A p value < 0.05 was considered significant (*). 
Stability of freeze-dried lipoplexes 255
The stability of the freeze-dried pegylated lipoplexes was evaluated after storage at 4°C in 256 closed glass vials for 1 month. The mean size, the PdI and the zeta potential were measured. should to a high extent resemble the human vaginal mucus [24] . 305
As demonstrates in figure 5 .A, the lipoplexes were able to freely diffuse in RNAse free water. 306
The peak values of the diffusion distributions varied from 0.7 µm 2 /s for the lipoplexes with 307 DSPE-PEG 750 to 1.3 µm 2 /s for unpegylated lipoplexes. In SVF ( figure 5.B) , the lipoplexes are 308 still able to diffuse, but slower than in water. This difference of diffusion is highly likely ascribed 309 to the viscosity of SVF (~ 3 mPa.s) and its complex composition. In SVF, lipoplexes have to 310 pass through the different components of mucus and particularly through the crosslinked mucin 311 fibres, which form a highly heterogeneous mesh. These results underline also the necessity to 312 measure the diffusion directly in the relevant biofluids rather than in diluted fluids. Despite the 313 DSPE-PEG 750 and without PEG, the aggregation was more pronounced as particles with a 337 diameter ranging from 300 to 500 nm were measured. 338
The size distributions outcomes confirm our hypothesis: coating lipoplexes with PEG 2000 can 339 minimize adhesive interactions between nanoparticles and mucus constituents, compared to 340 PEG 750 and without PEG, decreasing aggregation phenomenon and slightly increasing the 341 diffusion. The data stand in line with another previous study by J. das Neves et al [25] . 342 Moreover, it is well known that the size is a major requirement for an optimal vaginal diffusion 343 and it has been demonstrated that particles with a diameter around 200 to 300 nm show the 344 best diffusive property contrarily to particles with a diameter higher than 500 nm [27, 30] . 
Release of the siRNA 351
The release of siRNA from lipoplexes was evaluated using Fluorescence Correlation 352
Spectroscopy (FCS). FCS is a technique used to calculate the percentage of complexed fluo-353
siRNA by the lipoplexes and to follow its release as a function of time, as described previously 354 
Lipoplexes effect on the characteristics of the sponges 383
Placebo sponges, with different amounts of polymer (HEC) and plasticizer (PEG) were 384 previously characterized [19] . As the polymer concentration directly influences the viscosity 385 and probably the diffusion of lipoplexes, two concentrations of HEC were tested (0.83% and 386 1.67%). Moreover, the effect of the lipoplexes on the sponge's characteristics (mucoadhesion, 387 hardness, deformability and morphology) was also investigated. 388
Mucoadhesion 389
HEC polymer has been chosen to prepare the sponges for its well-described mucoadhesive 390
properties [22] . It has the possibility to anchor the formulation in the administration site and 391 allows a prolonged delivery of the incorporated material, thereby maximizing the clinical 392 performance [40] . Moreover, this polymer is considered as a non-toxic and non-irritating 393 material. Thanks to its biocompatible property, it has been employed in several commercialized 394 products intended for a vaginal use [4, 18, 41] . 395
In this section, the ability of the sponges to adhere to a partially hydrated mucin disc, mimicking 396 vaginal conditions, was studied. The mucoadhesive strength (N) was determined by the force 397 required to separate the disc from the sponge. 
Hardness and deformability 424
Topical application of sponges requires an insight to their behaviour after compression 425 stresses. These systems should possess suitable mechanical resistance to facilitate the 426 application inside vagina and also enough resistance to deformation to ensure durability 427 against shear stress encountered. The hardness is directly correlated with the polymer 428 concentration (figure 9.A); sponges with 1.67% are harder than sponges with 0.83% HEC (~ 1 429 N vs ~ 0.7 N). Moreover, the presence of trehalose and lipoplexes has no significant influence 430 (p > 0.05) on this characteristic. Since there are no reference values for optimal hardness, the 431 ability of sponges to be easily removed out of their containers and their malleability were also 432 analysed. Indeed, all sponges met these conditions; they are hard enough to be extracted 433 without being broken, they are malleable and retain their shape. Regarding the deformability 434 ( figure 9.B) , the slopes of the curves provide information about the deformability of sponges. 435
An increase in the slope corresponds to an increase deformability of the sponge. Specifically, 436 the sponges with 1.67% show around 10% of deformability while those containing 0.83% are 437 deformed at maximum 20%. Again, the presence of trehalose and lipoplexes does not change 438 the deformability. Their size is around 250 nm, in agreement with the sizes obtained using DLS and fSPT in the 451 previous sections (3. 1.2. and 3.2.1.) . In order to demonstrate that these spherical asperities 452 correspond to intact lipoplexes, an elemental analyse was performed. This technique was used 453 to confirm the presence of the phosphorous atom (P) and thus the presence of the siRNA in 454 the observed vesicles. Figure 11 shows that the P atom was detected in the sponge containing 455 1.67% HEC, 1% trehalose and lipoplexes (same results were observed for sponges with 0.83% 456 HEC while no P detection was observed with placebo sponges, data not shown). This confirms 457 that observed vesicles are lipoplexes. After being incorporated into the hydrogel and freeze-458 When applied in the vagina, sponges have to rehydrate with mucus to form a hydrogel. 472
Lipoplexes will have to progressively diffuse through the gel and then through the vaginal 473 mucus to reach vaginal epithelium. Therefore it is necessary to determine the diffusion ability 474 of lipoplexes and their stability into the rehydrated sponges. Moreover, the influence of HEC 475 concentration was also studied. fSPT and FCS techniques, as described previously, were used 476 for these analyses. Sponges were rehydrated with SVF at 37°C, mimicking vaginal conditions. 477
As shown in figure 12.A, lipoplexes have different diffusion profiles in the two types of gels 478 (0.83% vs 1.67 % HEC). In gels with 0.83% HEC, there are two populations of particles: a 479 large majority with a high peak value (D ~ 0.8 µm 2 /s) and some others particles with a lower 480 peak value of the diffusion distribution (D ~ 0.2 µm 2 /s). Regarding the measured sizes of these 481 lipoplexes, there are also two populations; a large majority with a diameter at around 200 nm 482 and also a little fraction of particles with a peak diameter around 90 nm (data not shown). 483
Indeed, particles with a diameter around 200 -300 nm can better diffuse in mucus than smaller 484 with a diameter below 100 nm [16] . Lipoplexes are also able to diffuse in gels with 1.67% HEC 485 but slower than in the 0.83% HEC gels (D ~ 0.4 µm 2 /s). The difference in viscosity of the two 486 hydrogels before and after freeze drying can explain this (100 mPa.s for the 0.83% HEC 487 hydrogel and 1300 mPa.s. for the 1.67% HEC hydrogel). Moreover, sponges were rehydrated 488 with SVF which also increases the viscosity of the final hydrogel. This can consequently further 489 reduce the mobility of lipoplexes. 490
The stability of lipoplexes (siRNA release) in the hydrogel (figure 12.B) was next assessed. Finally, the release rate of lipoplexes from rehydrated sponges was monitored over time and 502 compared for both types of sponges (0.83% vs 1.67% HEC). By employing fSPT, videos were 503
recorded in order to demonstrate the presence of lipoplexes in the acceptor compartment filled 504 with SVF and consequently their diffusion outside the rehydrated system (see on figure 1 ). 505 Figure 13 represents screenshots of these videos (A=1.67% and B=0.83% HEC). This 506 qualitative technique is used to show the number of lipoplexes diffusing in the mucus and if it 507 increases with time. 508
It is first observed that no lipoplexes were in the acceptor compartment at time 0, independently 509 of the HEC concentration. A lag time is necessary for the rehydration of sponges and to allow 510 the diffusion of lipoplexes. Then, fluorescent spots appear progressively in the acceptor 511 compartment with a delay difference of 2 hours between the two sponges. Lipoplexes appear 512 in the acceptor compartment after two hours for 0.83% HEC sponges (B) while they appeared 513 after four hours for 1.67% HEC sponges (A). These spots confirm that lipoplexes are able to 514 diffuse through sponges rehydrated with artificial vaginal fluids (section 3.4.). The appearance 515 delay of lipoplexes in the receiving compartment depends on the HEC concentration; the 516 higher the concentration of HEC, the longer the rehydration duration of the sponges. Moreover, 517 increasing the concentration of HEC results in gels with higher viscosity values. These two 518 phenomena delay the diffusion of the lipoplexes in the gel and in the receiving compartment. 519
Despite the different viscosities, lipoplexes were able in both cases to diffuse from the 520 rehydrated sponges even after 6 hours at 37°C. The increased amount of fluorescent spots 521 suggests an increase of lipoplexes release. This last point demonstrates that the sponges can 522 be considered as a matrix system allowing a sustained delivery of lipoplexes. 
Conclusions 528
This study shows the feasibility of entrapping pegylated lipoplexes into a solid matrix system 529 for a prolonged delivery of siRNA in vaginal mucus. The sponge system is obtained by freeze-530 drying and is intended to be administered directly inside vagina in order to treat pathologies 531 using the gene silencing mechanism. For this, the sponges have to be in situ rehydrated to 532 form a hydrogel and allow a sustained release of lipoplexes. Hydroxyethyl-cellulose (HEC) was 533 chosen to prepare the sponges for its mucoadhesive properties. 534
Vaginal administration of lipoplexes is a challenge since the mucus presents a significant 535 barrier to effective delivery. To overcome this, 30% of three types of PEG derivatives were 536 In order to be administered into the vagina and to ensure a prolonged delivery of the lipoplexes, 545 the sponges must meet acceptable mechanical characteristics such as ease of manipulation, 546 low hardness and good bioadhesion. Furthermore, lipoplexes have to be intact inside the 547
sponges. As our analysis shows, the sponges containing lipoplexes meet these criteria. 548
Sponges are hard enough to be malleable and flexible; what is important for an easy 549 application. The maximum percentage of deformation is around 20%, which could be enough 550 to resist to shear stress inside vagina. The strength necessary to separate the hydrated mucin 551 disc from the surface of the sponge is almost 0.7 N which is higher than for commercialized 552 vaginal products and could be sufficient to obtain an appropriate retention during the 553 therapeutic period. In addition, lipoplexes, incorporated in sponges, retain their morphology 554 and their original size. 555
To mimic vaginal conditions, sponges were rehydrated with SVF. The diffusion of lipoplexes 556 inside and outside the rehydrated sponges was measured. Depending on the HEC 557 concentration, lipoplexes present two different diffusion profiles. The diffusion is slower in the 558 sponges containing 1.67% of HEC than in those containing 0.83% of HEC. This observation is 559 the same for the diffusion outside the system. The release rate is lower in the 1.67% HEC 560
sponges. This can be explained by the fact that sponges with higher quantities of HEC need 561 more time to be rehydrated and that they have a higher viscosity after in situ rehydration. These 562 two phenomena delay the diffusion of the lipoplexes inside the gel and in the receiving 563 compartment. Considering that it takes 4 hours for lipoplexes to diffuse outside rehydrated 564 sponge with 1.67%, the sponges containing 0.83% HEC should be more suited for an optimal 565 vaginal treatment. 566
In conclusion, a new mucoadhesive solid system adapted for a prolonged vaginal delivery of 567 lipoplexes has been developed. It is easy to handle, able to protect pegylated lipoplexes and 568 to be rehydrated with vaginal fluids. In future studies, this promising freeze-dried 569 mucoadhesive sustained released system will be validated with active siRNA. 570 571
